Biohaven-JPM-20240108.pdf

1、TIA,Living with OCDAND HELPING RECRUIT IN BIOHAVEN CLINICAL TRIALS42nd Annual J.P.Morgan Healthcare ConferenceVlad Coric,M.D.Chairman and Chief Executive OfficerJanuary 8,2024 2024 Biohaven,Ltd.All rights reserved.Forward-Looking StatementThis presentation includes forward-looking statements within

2、the meaning of the Private Securities Litigation Reform Act of 1995,including statements about Biohaven Ltd.(the“Company”)and our planned and ongoing clinical trials,the timing of and the availability of data from those trials,the timing and our decisions to proceed with our planned regulatory filin

3、gs,the timing of and our ability to obtain regulatory approvals for our product candidates,the clinical potential utility of our product candidates,alone and as compared to other existing potential treatment options,and the potential advancement of our early phase programs.The use of certain words,i

4、ncluding“continue”,“plan”,“will”,“believe”,“may”,“expect”,“anticipate”and similar expressions,is intended to identify forward-looking statements.Investors are cautioned that any forward-looking statements,includingstatements regarding the future development,timing and potential marketing approval an

5、d commercialization of our development candidates,are not guarantees of future performance or results and involve substantial risks and uncertainties.Actual results,developments and events may differ materially from those in the forward-looking statements as a result of various factors including:the

6、 expected timing,commencement and outcomes of Biohavens planned and ongoing clinical trials;the timing of planned interactions and filings with the FDA;the timing and outcome of expected regulatory filings;complying with applicable U.S.regulatory requirements;the potential commercialization of Bioha